Evidence map›Paper›PMID 39005423›Full record

ArticlebioRxiv : the preprint server for biology2024

Ketomimetic Nutrients Trigger a Dual Metabolic Defense in Breast Cancer Cells.

Mohini Kamra, Yuan-I Chen, Paula Delgado, Erin Seeley, Stephanie Seidlits, Hsin-Chih Yeh, Amy Brock, Sapun H Parekh

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yuan-I Chen
Paula Delgado
Stephanie SeidlitsORCID 0000-0003-3881-7166

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Using label-free Raman microscopy to predict therapeutic resistance of TNBC cellsU01CA253540 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI BROCK, AMY, YANKEELOV, THOMAS E · 2020 to 2024
$2.1M
Tissue-Engineered Models of Microvessel-Mediated Glioblastoma InvasionR01CA241927 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI SEIDLITS, STEPHANIE KRISTIN · 2020 to 2024
$1.9M
Engineered microenvironments as biomimetic culture platforms for studying the role of brain extracellular matrix in acquisition of resistance to EGFR inhibition across multiple biological scalesR21NS093199 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NATHANSON, DAVID A., SEIDLITS, STEPHANIE KRISTIN · 2015 to 2016
$424k
Studying synaptic transmission under opioid exposure using hiPSC-derived midbrain model and hyperspectral fluorescence lifetime imagingR21DA060543 · NIDA · UNIVERSITY OF TEXAS AT AUSTIN · PI SEIDLITS, STEPHANIE KRISTIN, YEH, HSIN-CHIH · 2024 to 2025
$404k
NCI NIH HHS 75N91019D00024NCI NIH HHS R01 CA241927NCI NIH HHS U01 CA253540NIDA NIH HHS R21 DA060543NINDS NIH HHS R21 NS093199
6 · The paper itself

Abstract

While the triggers for the metastatic transformation of breast cancer (BC) cells remain unknown, recent evidence suggests that intrinsic cellular metabolism could be a crucial driver of migratory disposition and chemoresistance. Aiming to decode the molecular mechanisms involved in BC cell metabolic maneuvering, we study how a ketomimetic (ketone body rich, low glucose) medium affects Doxorubicin (DOX) susceptibility and invasive disposition of BC cells. We quantified glycocalyx sialylation and found an inverse correlation with DOX-induced cytotoxicity and DOX internalization. These measurements were coupled with single-cell metabolic imaging, bulk migration studies, along with transcriptomic and metabolomic analyses. Our findings revealed that a ketomimetic medium enhances chemoresistance and invasive disposition of BC cells via two main oncogenic pathways: hypersialylation and lipid synthesis. We propose that the crosstalk between these pathways, juxtaposed at the synthesis of the glycan precursor UDP-GlcNAc, furthers advancement of a metastatic phenotype in BC cells under ketomimetic conditions.

Identifiers

PMID39005423
PMCPMC11244981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.